Chronic News and Research

RSS

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naïve patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA, USA.

7 Nov 2011

Study provides blueprint for design of new HIV drugs

Scientists have moved a step closer to understanding how one of our body's own proteins helps stop the human immunodeficiency virus (HIV-1) in its tracks.

7 Nov 2011

MRSA co-infection increases risk of flu-related mortality among children

During the 2009 H1N1 influenza pandemic, many previously healthy children became critically ill, developing severe pneumonia and respiratory failure, sometimes fatal. The largest nationwide investigation to date of influenza in critically ill children, led by Children's Hospital Boston, found one key risk factor: Simultaneous infection with methicillin-resistant Staphylococcus aureus (MRSA) increased the risk for flu-related mortality 8-fold among previously healthy children.

7 Nov 2011

Patients with lupus nephritis ESRD choose hemodialysis as initial therapy

Newly published research shows that more patients with end-stage renal disease (ESRD) caused by lupus nephritis choose hemodialysis as their initial kidney replacement therapy over peritoneal dialysis and preemptive kidney transplantation.

7 Nov 2011

$Narcotic analgesics increase risk of falls and fractures among elderly$

Narcotic analgesics increase risk of falls and fractures among elderly

Falls and fractures among senior citizens have increased since rofecoxib was removed from the market in 2004, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex Pharmaceuticals Incorporated today announced positive interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with chronic genotype 1 hepatitis C (HCV) and human immunodeficiency virus.

7 Nov 2011

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

Abbott today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA (adalimumab) plus methotrexate (MTX) for up to eight years in patients with early moderate to severe rheumatoid arthritis (RA) and up to 10 years in patients with long-standing moderate to severe RA, respectively.

7 Nov 2011

RA patients with low levels of inflammation less likely to develop cardiovascular disease

According to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago, patients with rheumatoid arthritis who have low levels of inflammatory disease activity have lower risk for heart complications and stroke.

7 Nov 2011

Early treatment with rheumatologist may decrease costly interventions in people with RA

Early and appropriate treatment by a rheumatologist may decrease costly interventions —such as orthopedic surgery — in people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Rheumavax safe and feasible in treating RA

A vaccine designed to re-educate the immune system has been shown to be safe and feasible in the treatment of rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

$New data from Savient's KRYSTEXXA Phase III trial on refractory chronic gout$

New data from Savient's KRYSTEXXA Phase III trial on refractory chronic gout

Savient Pharmaceuticals, Inc. announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.

7 Nov 2011

Vitamin D supplementation benefits people with lupus

The first study to report the effects vitamin D has on the immune system of people with lupus was reported this week a the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Exposure to air pollution may increase risk of RA

Exposure to some types of air pollution, especially sulfur dioxide — one of the six most common pollutants in the United States — is associated with a somewhat increased risk of developing rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Children with polyarticular JIA benefit from early and aggressive therapy

Children with juvenile arthritis who are treated early and aggressively have better outcomes, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Biologics reduce fatigue in people with RA

Treatment with a biologic agent reduces fatigue in people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

IFNa-kinoid shows promise against lupus

The first study to show results using active immunotherapy against the signaling protein interferon alpha in the treatment of lupus will be presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Link between use of anti-TNF therapy and malignant melanoma in RA patients

According to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago, people taking anti-tumor necrosis factor therapies to treat rheumatoid arthritis have a higher risk of developing malignant melanoma.

7 Nov 2011

Study finds pregnancy safe for 80% of women with lupus

Promising research led by investigators at Hospital for Special Surgery may offer hope for women with lupus who once thought that pregnancy was too risky.

7 Nov 2011

Patients with RA have lower expectations about postsurgical outcomes after TKA

Compared with osteoarthritis patients, individuals with rheumatoid arthritis who undergo total knee replacement surgery have lower expectations about their postsurgical outcomes, according to a new study by researchers at Hospital for Special Surgery (HSS) in New York City.

6 Nov 2011

$Women under 50 with RA more likely to have new fractures$

Women under 50 with RA more likely to have new fractures

Women under 50 with rheumatoid arthritis are at greater risk of breaking bones than women without the condition, according to a Mayo Clinic study being presented at the American College of Rheumatology annual scientific meeting in Chicago.

6 Nov 2011